[HTML][HTML] Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer
Tyrosine kinase inhibitors were found to be clinically effective for treatment of patients with
certain subsets of cancers carrying somatic mutations in receptor tyrosine kinases. However …
certain subsets of cancers carrying somatic mutations in receptor tyrosine kinases. However …
Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer
AF Aissa, AB Islam, MM Ariss, CC Go… - Nature …, 2021 - ideas.repec.org
Tyrosine kinase inhibitors were found to be clinically effective for treatment of patients with
certain subsets of cancers carrying somatic mutations in receptor tyrosine kinases. However …
certain subsets of cancers carrying somatic mutations in receptor tyrosine kinases. However …
Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer.
AF Aissa, AB Islam, MM Ariss, CC Go… - Nature …, 2021 - search.ebscohost.com
Tyrosine kinase inhibitors were found to be clinically effective for treatment of patients with
certain subsets of cancers carrying somatic mutations in receptor tyrosine kinases. However …
certain subsets of cancers carrying somatic mutations in receptor tyrosine kinases. However …
Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer
AF Aissa, AB Islam, MM Ariss, CC Go… - Nature …, 2021 - econpapers.repec.org
Tyrosine kinase inhibitors were found to be clinically effective for treatment of patients with
certain subsets of cancers carrying somatic mutations in receptor tyrosine kinases. However …
certain subsets of cancers carrying somatic mutations in receptor tyrosine kinases. However …
Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer
AF Aissa, AB Islam, MM Ariss, CC Go… - Nature …, 2021 - pubmed.ncbi.nlm.nih.gov
Tyrosine kinase inhibitors were found to be clinically effective for treatment of patients with
certain subsets of cancers carrying somatic mutations in receptor tyrosine kinases. However …
certain subsets of cancers carrying somatic mutations in receptor tyrosine kinases. However …
[HTML][HTML] Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer
AF Aissa, AB Islam, MM Ariss, CC Go… - Nature …, 2021 - ncbi.nlm.nih.gov
Tyrosine kinase inhibitors were found to be clinically effective for treatment of patients with
certain subsets of cancers carrying somatic mutations in receptor tyrosine kinases. However …
certain subsets of cancers carrying somatic mutations in receptor tyrosine kinases. However …
Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer
AF Aissa, AB Islam, MM Ariss, CC Go… - Nature …, 2021 - ui.adsabs.harvard.edu
Tyrosine kinase inhibitors were found to be clinically effective for treatment of patients with
certain subsets of cancers carrying somatic mutations in receptor tyrosine kinases. However …
certain subsets of cancers carrying somatic mutations in receptor tyrosine kinases. However …
Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer.
AF Aissa, I ABMMK, MM Ariss, CC Go… - Nature …, 2021 - europepmc.org
Tyrosine kinase inhibitors were found to be clinically effective for treatment of patients with
certain subsets of cancers carrying somatic mutations in receptor tyrosine kinases. However …
certain subsets of cancers carrying somatic mutations in receptor tyrosine kinases. However …
[PDF][PDF] Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer
AF Aissa, AB Islam, MM Ariss, CC Go, AE Rader… - academia.edu
Results Discovery of drug-tolerant states in PC9 cells treated with erlotinib. First-generation
inhibitors such as erlotinib have revolutionized the treatment of EGFR-mutant NSCLCs. PC9 …
inhibitors such as erlotinib have revolutionized the treatment of EGFR-mutant NSCLCs. PC9 …
[PDF][PDF] Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer
AF Aissa, AB Islam, MM Ariss, CC Go, AE Rader… - academia.edu
Results Discovery of drug-tolerant states in PC9 cells treated with erlotinib. First-generation
inhibitors such as erlotinib have revolutionized the treatment of EGFR-mutant NSCLCs. PC9 …
inhibitors such as erlotinib have revolutionized the treatment of EGFR-mutant NSCLCs. PC9 …